Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks

Lung Cancer Clinical Trial

— ALPINE  

Official title:

Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05902559
• Other study ID #: 155581
• Status: Not yet recruiting
• Start date: August 2023
• Est. completion date: November 20, 2028

Study information

• Verified date: June 2023
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Low-dose CT (LDCT) screening for lung cancer (LCS) has been shown to reduce lung cancer specific mortality in multiple randomised controlled trials. However, although LDCT screening has been demonstrated to reduce cancer- specific mortality, there remain outstanding questions regarding how screening can be implemented. In particular, indeterminate nodules are common, and can be challenging to distinguish from benign nodules on CT appearances alone. Furthermore, distinguishing cancers which are likely to become clinically significant from those that will remain indolent is challenging, but essential to prevent over-treatment and overdiagnosis. There is significant interest in using a multi-modal approach to LCS, incorporating biomarkers obtained from minimally-invasive samples alongside LDCT to improve ability to recognise clinically-significant lung cancers at an early stage. The Targeted Lung Health Check (TLHC) programme is an NHS programme with the aim of using LDCT screening in appropriately high-risk individuals to improve early diagnosis and survival in lung cancer. The North Central London TLHC programme started in December 2022. The purpose of the ALPINE study is to develop a platform to allow collection of minimally-invasive samples from participants undergoing screening within the North Central London TLHC programme. The use of such biomarkers in the diagnosis of lung cancer is a rapidly developing field and novel techniques and technologies are continuously under development. The ALPINE study will generate a cohort with matched biosamples, CT scans and clinical data which will be uniquely well placed to serve to develop or validate biomarkers in lung cancer screening and risk prediction.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10000
• Est. completion date: November 20, 2028
• Est. primary completion date: November 20, 2027
• Gender: All
• Age group: 55 Years to 74 Years

Eligibility

Inclusion Criteria:

• Attended one of more visits as part of the NCL NHS TLHC programme
• Adults aged between 55 years and 74 years and 364 days
• Have capacity and can provide written consent

Exclusion Criteria:

• Declines participation in ALPINE
• Lacking capacity and unable to provide written consent
• Patients who are considered by the clinician to be unfit/not suitable for enrolment in ALPINE

Related Conditions & MeSH terms

• Lung Cancer

Locations

Country	Name	City	State
United Kingdom	University College London Hospitals NHS Foundation Trust	London

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To identify novel molecular, immune and clinical biomarkers to improve the sensitivity and specificity of lung cancer screening beyond what is achieved with conventional risk prediction models and low-dose CT scanning.	This includes proteomics, metabolomics, genomics and immune repertoire characterization performed on peripheral bloods.	5 years